175 related articles for article (PubMed ID: 30262205)
1. [LY2963016 insulin glargine: The first biosimilar insulin approved in the European Union].
Altman JJ; Chevalier N; Delemer B; Travert F; Benabbad I
Presse Med; 2018 Oct; 47(10):854-866. PubMed ID: 30262205
[TBL] [Abstract][Full Text] [Related]
2. LY2963016 Insulin Glargine: A Review in Type 1 and 2 Diabetes.
Lamb YN; Syed YY
BioDrugs; 2018 Feb; 32(1):91-98. PubMed ID: 29368288
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of LY2963016 insulin glargine in patients with type 1 and type 2 diabetes previously treated with insulin glargine.
Hadjiyianni I; Dahl D; Lacaya LB; Pollom RK; Chang CL; Ilag LL
Diabetes Obes Metab; 2016 Apr; 18(4):425-9. PubMed ID: 26749289
[TBL] [Abstract][Full Text] [Related]
4. Single-dose euglycaemic clamp studies demonstrating pharmacokinetic and pharmacodynamic similarity between MK-1293 insulin glargine and originator insulin glargine (Lantus) in subjects with type 1 diabetes and healthy subjects.
Crutchlow MF; Palcza JS; Mostoller KM; Mahon CD; Barbour AM; Marcos MC; Xu Y; Watkins E; Morrow L; Hompesch M
Diabetes Obes Metab; 2018 Feb; 20(2):400-408. PubMed ID: 28817223
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of immunogenicity of LY2963016 insulin glargine compared with Lantus® insulin glargine in patients with type 1 or type 2 diabetes mellitus.
Ilag LL; Deeg MA; Costigan T; Hollander P; Blevins TC; Edelman SV; Konrad RJ; Ortmann RA; Pollom RK; Huster WJ; Zielonka JS; Prince MJ
Diabetes Obes Metab; 2016 Feb; 18(2):159-68. PubMed ID: 26434665
[TBL] [Abstract][Full Text] [Related]
6. In brief: Semglee - insulin glargine interchangeable with Lantus.
Med Lett Drugs Ther; 2021 Oct; 63(1634):159-160. PubMed ID: 34550958
[No Abstract] [Full Text] [Related]
7. Immunogenicity, efficacy, and safety of biosimilar insulin glargine (Gan & Lee glargine) compared with originator insulin glargine (Lantus®) in patients with type 2 diabetes after 26 weeks' treatment: A randomized open label study.
Christofides EA; Puente O; Norwood P; Denham D; Maheshwari H; Lillestol M; Hart T; Nakhle S; Chadha A; Fitz-Patrick D; Sugimoto D; Soufer J; Young D; Warren M; Huffman D; Reed J; Bays H; Arora S; Rizzardi B; Tidman R; Rendell M; Johnson KA
Diabetes Obes Metab; 2024 Jun; 26(6):2412-2421. PubMed ID: 38558508
[TBL] [Abstract][Full Text] [Related]
8. MYL1501D Insulin Glargine: A Review in Diabetes Mellitus.
Hoy SM
BioDrugs; 2020 Apr; 34(2):245-251. PubMed ID: 32215829
[TBL] [Abstract][Full Text] [Related]
9. Biosimilars and Novel Insulins.
Ampudia-Blasco FJ
Am J Ther; 2020; 27(1):e52-e61. PubMed ID: 31764128
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of MYL-1501D vs insulin glargine in patients with type 1 diabetes after 52 weeks: Results of the INSTRIDE 1 phase III study.
Blevins TC; Barve A; Sun B; Ankersen M
Diabetes Obes Metab; 2018 Aug; 20(8):1944-1950. PubMed ID: 29656504
[TBL] [Abstract][Full Text] [Related]
11. Safety, Immunogenicity, and Glycemic Control of Insulin Aspart Biosimilar SAR341402 Versus Originator Insulin Aspart in People with Diabetes Also Using Insulin Glargine: 12-Month Results from the GEMELLI 1 Trial.
Garg SK; Wernicke-Panten K; Wardecki M; Kramer D; Delalande F; Franek E; Sadeharju K; Monchamp T; Miossec P; Mukherjee B; Shah VN
Diabetes Technol Ther; 2020 Jul; 22(7):516-526. PubMed ID: 32068436
[No Abstract] [Full Text] [Related]
12. Treatment satisfaction, safety, and effectiveness of biosimilar insulin glargine is comparable in patients with type 2 diabetes mellitus after switching from insulin glargine or insulin degludec: a post-marketing safety study.
Taki K; Koyanagi M; Nagaoka S; Shingaki T
Curr Med Res Opin; 2020 Dec; 36(12):1975-1983. PubMed ID: 33030354
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of LY2963016 insulin glargine compared with insulin glargine (Lantus®) in patients with type 1 diabetes in a randomized controlled trial: the ELEMENT 1 study.
Blevins TC; Dahl D; Rosenstock J; Ilag LL; Huster WJ; Zielonka JS; Pollom RK; Prince MJ
Diabetes Obes Metab; 2015 Aug; 17(8):726-33. PubMed ID: 25974640
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and Safety of Insulin Aspart Biosimilar SAR341402 Versus Originator Insulin Aspart in People with Diabetes Treated for 26 Weeks with Multiple Daily Injections in Combination with Insulin Glargine: A Randomized Open-Label Trial (GEMELLI 1).
Garg SK; Wernicke-Panten K; Wardecki M; Kramer D; Delalande F; Franek E; Sadeharju K; Monchamp T; Mukherjee B; Shah VN
Diabetes Technol Ther; 2020 Feb; 22(2):85-95. PubMed ID: 31804851
[No Abstract] [Full Text] [Related]
15. Efficacy and safety of MYL-1501D versus insulin glargine in patients with type 2 diabetes after 24 weeks: Results of the phase III INSTRIDE 2 study.
Blevins TC; Barve A; Sun B; Raiter Y; Aubonnet P; Muniz R; Athalye S; Ankersen M
Diabetes Obes Metab; 2019 Jan; 21(1):129-135. PubMed ID: 30112792
[TBL] [Abstract][Full Text] [Related]
16. Immunogenicity of LY2963016 insulin glargine and Lantus® insulin glargine in Chinese patients with type 1 or type 2 diabetes mellitus.
Wang W; Song X; Lou Y; Du L; Zhu D; Zhou Z
Diabetes Obes Metab; 2022 Jun; 24(6):1094-1104. PubMed ID: 35187770
[TBL] [Abstract][Full Text] [Related]
17. Similar efficacy and safety of LY2963016 insulin glargine and insulin glargine (Lantus®) in patients with type 2 diabetes who were insulin-naïve or previously treated with insulin glargine: a randomized, double-blind controlled trial (the ELEMENT 2 study).
Rosenstock J; Hollander P; Bhargava A; Ilag LL; Pollom RK; Zielonka JS; Huster WJ; Prince MJ
Diabetes Obes Metab; 2015 Aug; 17(8):734-41. PubMed ID: 25931141
[TBL] [Abstract][Full Text] [Related]
18. Biosimilar vs originator insulins: Systematic review and meta-analysis.
Yamada T; Kamata R; Ishinohachi K; Shojima N; Ananiadou S; Nom H; Yamauchi T; Kadowaki T
Diabetes Obes Metab; 2018 Jul; 20(7):1787-1792. PubMed ID: 29536603
[TBL] [Abstract][Full Text] [Related]
19. Similar immunogenicity profiles between the proposed biosimilar MYL-1501D and reference insulin glargine in patients with diabetes mellitus: the phase 3 INSTRIDE 1 and INSTRIDE 2 studies.
Sun B; Sengupta N; Rao A; Donnelly C; Waichale V; Roy AS; Ramaswamy S; Pathak D; Bowsher RR; Raiter Y; Aubonnet P; Barve A
BMC Endocr Disord; 2021 Jun; 21(1):129. PubMed ID: 34174848
[TBL] [Abstract][Full Text] [Related]
20. [Comparison of two insulin glargine formulations: biosimilar vs. reference product].
Mönnig E; Schloot N; Hohberg C; Wiesner T; Heinemann L
MMW Fortschr Med; 2016 Aug; 158 Suppl 5():19-27. PubMed ID: 27565486
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
